Literature DB >> 15994003

EAU guidelines on the diagnosis and treatment of urothelial carcinoma in situ.

Adrian P M van der Meijden1, Richard Sylvester, Willem Oosterlinck, Eduardo Solsona, Andreas Boehle, Bernard Lobel, Erkki Rintala.   

Abstract

OBJECTIVES: On behalf of the European Association of Urology (EAU), guidelines for the diagnosis, therapy and follow-up of patients with urothelial carcinoma in situ (CIS) have been established.
METHOD: The recommendations in these guidelines are based on a recent comprehensive overview and meta-analysis in which two panel members have been involved (RS and AVDM). A systematic literature search was conducted using Medline, the US Physicians' Data Query (PDQ), the Cochrane Central Register of Controlled Trials, and reference lists in trial publications and review articles.
RESULTS: Recommendations are provided for the diagnosis, conservative and radical surgical treatment, and follow-up of patients with CIS. Levels of evidence are influenced by the lack of large randomized trials in the treatment of CIS.

Entities:  

Mesh:

Year:  2005        PMID: 15994003     DOI: 10.1016/j.eururo.2005.05.011

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  17 in total

Review 1.  [Standards and perspectives in diagnosis and therapy of bladder carcinoma].

Authors:  C Stief; D Zaak; M Stöckle; U Studer; R Knuechel; C Rödel; R Sauer; H Rubben
Journal:  Urologe A       Date:  2006-09       Impact factor: 0.639

Review 2.  Photodynamic diagnostics of bladder tumors.

Authors:  Stefan Denzinger; Maximilian Burger
Journal:  Curr Urol Rep       Date:  2008-03       Impact factor: 3.092

Review 3.  [Fluorescence cystoscopy. Perspective in clinical practice and research].

Authors:  P Jichlinski; B Lovisa; C Erling; D Aymon; H van den Berg; G Wagnieres
Journal:  Urologe A       Date:  2008-08       Impact factor: 0.639

Review 4.  [Chemotherapy: from bacteria killer to antitumor agent : A striking transformation in the term over the last century].

Authors:  J Konert
Journal:  Urologe A       Date:  2017-11       Impact factor: 0.639

5.  Best practice in the treatment of nonmuscle invasive bladder cancer.

Authors:  Anastasios Anastasiadis; Theo M de Reijke
Journal:  Ther Adv Urol       Date:  2012-02

6.  Photodynamic diagnosis in patients with T1G3 bladder cancer: influence on recurrence rate.

Authors:  Peter Stanislaus; Dirk Zaak; Thomas Stadler; Stefan Tritschler; Ruth Knüchel; Christian G Stief; Alexander Karl
Journal:  World J Urol       Date:  2010-06-26       Impact factor: 4.226

Review 7.  Hexyl aminolevulinate: in the detection of bladder cancer.

Authors:  James E Frampton; Greg L Plosker
Journal:  Drugs       Date:  2006       Impact factor: 9.546

8.  Saudi Oncology Society clinical management guidelines for urinary bladder cancer.

Authors:  Khaled Al Othman; Shouki Bazarbashi; Khalid Balaraj; Mohamed Al Otaibi; Baher Kamal; Ibraheem Al Oraifi; Eyad Al Saeed; Khalid Al Gamdi; Ali Jubran; Ahmad Salah; Jalal Al Shareef; Jamal Zekri
Journal:  Urol Ann       Date:  2011-03

9.  [Secondary prevention after urological tumor diseases. Focusing on the kidneys, testes, and bladder].

Authors:  M J Mathers; D A Lazica; T Klotz; F Sommer; S Roth
Journal:  Urologe A       Date:  2007-06       Impact factor: 0.639

Review 10.  [Fluorescence cystoscopy at bladder cancer: present trials].

Authors:  D Zaak; A Karl; H Stepp; S Tritschler; D Tilki; M Burger; R Knuechel; C Stief
Journal:  Urologe A       Date:  2007-11       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.